-
1
-
-
84896525622
-
Similarities and differences in the oncology drug approval process between fda and european union with emphasis on in vitro companion diagnostics
-
Senderowicz AM, Pfaff O. Similarities and differences in the oncology drug approval process between FDA and European Union with emphasis on in vitro companion diagnostics. Clin Cancer Res 2014; 20:1445-52.
-
(2014)
Clin Cancer Res
, vol.20
, pp. 1445-1452
-
-
Senderowicz, A.M.1
Pfaff, O.2
-
4
-
-
84896514438
-
-
European Medicines Agency Committee for Human Medicinal Products. Reflection paper on methodological issues with pharmacogenomic biomarkers in relation to clinical development and patient selection (draft). London (UK): The Agency; 2011 Jun. Report No.: EMA/446337/2011
-
European Medicines Agency, Committee for Human Medicinal Products. Reflection paper on methodological issues with pharmacogenomic biomarkers in relation to clinical development and patient selection (draft). London (UK): The Agency; 2011 Jun. Report No.: EMA/446337/2011.
-
-
-
-
5
-
-
84896513241
-
-
European Medicines Agency Committee for Human Medicinal Products. Reflection paper on co-development of pharmacogenomic biomarkers and assays in the context of drug development (draft). London (UK): The Agency; 2010 Jun. Report No.: EMA/CHMP/641298/
-
European Medicines Agency, Committee for Human Medicinal Products. Reflection paper on co-development of pharmacogenomic biomarkers and assays in the context of drug development (draft). London (UK): The Agency; 2010 Jun. Report No.: EMA/CHMP/641298/2008.
-
(2008)
-
-
-
6
-
-
84896522908
-
-
European Medicines Agency Committee for Human Medicinal Products. CHMP assessment report: Pixuvri (pixantrone). London, (UK): The Agency; 2012 Feb. Report No.: EMA/309145/2012
-
European Medicines Agency, Committee for Human Medicinal Products. CHMP assessment report: Pixuvri (pixantrone). London, (UK): The Agency; 2012 Feb. Report No.: EMA/309145/2012.
-
-
-
-
7
-
-
84896535145
-
-
European Medicines Agency, Oncology Working Party. Guideline on the evaluation of anticancer medicinal products in man. London (UK): The Agency; 2012 Dec. Report No.: EMA/CHMP/205/95/Rev.4
-
European Medicines Agency, Oncology Working Party. Guideline on the evaluation of anticancer medicinal products in man. London (UK): The Agency; 2012 Dec. Report No.: EMA/CHMP/205/95/Rev.4.
-
-
-
-
8
-
-
84896498314
-
-
Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on in vitro diagnostic medical devices. OJ L 331, p. 1-37 (December 7, 1998)
-
Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on in vitro diagnostic medical devices. OJ L 331, p. 1-37 (December 7, 1998).
-
-
-
-
9
-
-
84896500987
-
-
Global Harmonization Task Force, Study Group 1 of the Global Harmonization Task Force. Principles for in vitro diagnostic (IVD) medical devices classification. 2008 Jul. Report No.: GHTF/SG1/N045
-
Global Harmonization Task Force, Study Group 1 of the Global Harmonization Task Force. Principles for in vitro diagnostic (IVD) medical devices classification. 2008 Jul. Report No.: GHTF/SG1/N045.
-
-
-
-
11
-
-
84896500742
-
-
Amendments adopted by the European Parliament on 22 October 2013 on the proposal for a regulation of the European Parliament and of the Council on in vitro diagnostic medical devices (COM(2012) 0541-C7-0317/2012-2012/0267(COD))
-
Amendments adopted by the European Parliament on 22 October 2013 on the proposal for a regulation of the European Parliament and of the Council on in vitro diagnostic medical devices (COM(2012)0541-C7-0317/2012-2012/0267(COD)). 2013.
-
, vol.2013
-
-
-
12
-
-
84896496628
-
-
European Commission. Citizens' summary: EU proposals on medical devices [Internet]. Brussels, Belgium: The Commission Available from
-
European Commission. Citizens' summary: EU proposals on medical devices [Internet]. Brussels, Belgium: The Commission; 2012. Available from: http://ec.europa.eu/health/medical-devices/files/revision-docs/ citizen-summary-20120926en.pdf.
-
, vol.2012
-
-
-
14
-
-
80053484515
-
Integrating predictive biomarkers and classifiers into oncology clinical development programmes
-
Beckman RA, Clark J, Chen C. Integrating predictive biomarkers and classifiers into oncology clinical development programmes. Nat Rev Drug Discov 2011;10:735-48.
-
(2011)
Nat Rev Drug Discov
, vol.10
, pp. 735-748
-
-
Beckman, R.A.1
Clark, J.2
Chen, C.3
-
15
-
-
84895905845
-
Biomarker enrichment strategies: Matching trial design to biomarker credentials
-
Epub 2013 Nov 26. doi: 10.1038/nrclinonc.2013.218
-
Freidlin B, Korn EL. Biomarker enrichment strategies: matching trial design to biomarker credentials. Nat Rev Clin Oncol 2013;11:81-90. Epub 2013 Nov 26. doi: 10.1038/nrclinonc.2013.218.
-
(2013)
Nat Rev Clin Oncol
, vol.11
, pp. 81-90
-
-
Freidlin, B.1
Korn, E.L.2
-
16
-
-
27744537954
-
Adaptive signature design: An adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients
-
Freidlin B, Simon R. Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clin Cancer Res 2005;11: 7872-8.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 7872-7878
-
-
Freidlin, B.1
Simon, R.2
-
17
-
-
69949102133
-
Confirmatory adaptive designs with bayesian decision tools for a targeted therapy in oncology
-
Brannath W, Zuber E, Branson M, Bretz F, Gallo P, Posch M, et al. Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology. Stat Med 2009;28:1445-63.
-
(2009)
Stat Med
, vol.28
, pp. 1445-1463
-
-
Brannath, W.1
Zuber, E.2
Branson, M.3
Bretz, F.4
Gallo, P.5
Posch, M.6
-
18
-
-
34648840242
-
Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset
-
Wang SJ, O'Neill RT, HungHM. Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset. Pharm Stat 2007;6:227-44.
-
(2007)
Pharm Stat
, vol.6
, pp. 227-244
-
-
Wang, S.J.1
O'Neill, R.T.2
Hung, H.M.3
-
20
-
-
84896499871
-
-
European Medicines Agency. CHMP assessment report: Xalkori (crizotinib). London (UK): The Agency; 2012 Jul. Report No.: EMA/CHMP/497137/2012
-
European Medicines Agency. CHMP assessment report: Xalkori (crizotinib). London (UK): The Agency; 2012 Jul. Report No.: EMA/CHMP/497137/2012.
-
-
-
-
21
-
-
84896509866
-
-
European Medicines Agency. CHMP assessment report: Vectibix (panitumumab). London (UK): The Agency; 2007 Dec. Report No.: EMEA/CHMP/394299/2007
-
European Medicines Agency. CHMP assessment report: Vectibix (panitumumab). London (UK): The Agency; 2007 Dec. Report No.: EMEA/CHMP/394299/2007
-
-
-
-
22
-
-
84896532982
-
-
European Medicines Agency. CHMP assessment report: Iressa (gefitinib). London (UK): The Agency; 2009 Jul. EMEA/CHMP/563746/2008
-
European Medicines Agency. CHMP assessment report: Iressa (gefitinib). London (UK): The Agency; 2009 Jul. EMEA/CHMP/563746/2008.
-
-
-
-
23
-
-
37349069551
-
Biomarker as a classifier in pharmacogenomics clinical trials: A tribute to 30th anniversary of psi
-
Wang SJ. Biomarker as a classifier in pharmacogenomics clinical trials: a tribute to 30th anniversary of PSI. Pharm Stat 2007;6: 283-96.
-
(2007)
Pharm Stat
, vol.6
, pp. 283-296
-
-
Wang, S.J.1
-
24
-
-
84896529457
-
Product information: Glivec (imatinib). London (uk): The agency; 2013 oct. Available from
-
European Medicines Agency. Product information: Glivec (imatinib). London (UK): The Agency; 2013 Oct. Available from: http://www.ema. europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000406/ human-med-000808.jsp&mid=WC0b01ac058001d124.
-
European Medicines Agency
-
-
-
25
-
-
84896514290
-
-
European Medicines Agency. CHMP assessment report: Caprelsa (vandetanib). London UK: The Agency; 2011 Nov. Report No.: EMA/128076/2012
-
European Medicines Agency. CHMP assessment report: Caprelsa (vandetanib). London, UK: The Agency; 2011 Nov. Report No.: EMA/128076/2012.
-
-
-
-
26
-
-
84863393080
-
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing
-
Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-92.
-
(2012)
N Engl J Med
, vol.366
, pp. 883-892
-
-
Gerlinger, M.1
Rowan, A.J.2
Horswell, S.3
Larkin, J.4
Endesfelder, D.5
Gronroos, E.6
-
27
-
-
84859438079
-
Hurdles in anticancer drug development from a regulatory perspective
-
Jonsson B, Bergh J. Hurdles in anticancer drug development from a regulatory perspective. Nat Rev Clin Oncol 2012;9:236-43.
-
(2012)
Nat Rev Clin Oncol
, vol.9
, pp. 236-243
-
-
Jonsson, B.1
Bergh, J.2
-
28
-
-
78449294101
-
Assessing the clinical utility of diagnostics used in drug therapy
-
Woodcock J. Assessing the clinical utility of diagnostics used in drug therapy. Clin Pharmacol Ther 2010;88:765-73.
-
(2010)
Clin Pharmacol Ther
, vol.88
, pp. 765-773
-
-
Woodcock, J.1
-
29
-
-
84896540649
-
Evidence of clinical utility: An unmet need in molecular diagnostics for patients with cancer
-
Parkinson DR, McCormack RT, Keating SM, Gutman SI, Hamilton SR, Mansfield EA, et al. Evidence of clinical utility: an unmet need in molecular diagnostics for patients with cancer. Clin Cancer Res 2014;20:1428-44.
-
(2014)
Clin Cancer Res
, vol.20
, pp. 1428-1444
-
-
Parkinson, D.R.1
McCormack, R.T.2
Keating, S.M.3
Gutman, S.I.4
Hamilton, S.R.5
Mansfield, E.A.6
-
30
-
-
84896535710
-
The health technology assessment of companion diagnostics: Experience of nice
-
Byron SK, Crabb N, George E, Marlow M, Newland A. The health technology assessment of companion diagnostics: experience of NICE. Clin Cancer Res 2014;20:1469-76.
-
(2014)
Clin Cancer Res
, vol.20
, pp. 1469-1476
-
-
Byron, S.K.1
Crabb, N.2
George, E.3
Marlow, M.4
Newland, A.5
-
31
-
-
84896537994
-
The proposed eu ivd regulation and its impact on diagnostic development. Scrip regulatory affairs. (21 jun 2013). 32. Mansfield ea.fda perspective on companion diagnostics: An evolving paradigm
-
Le Gledic S, Malek S. The proposed EU IVD Regulation and its impact on diagnostic development. Scrip Regulatory Affairs. (21 Jun 2013). 32. Mansfield EA.FDA perspective on companion diagnostics: an evolving paradigm. Clin Cancer Res 2014;20:1453-7.
-
(2014)
Clin Cancer Res
, vol.20
, pp. 1453-1457
-
-
Le Gledic, S.1
Malek, S.2
-
32
-
-
84896510407
-
-
European Commission. Impact assessment on the revision of the regulatory framework for medical devices. Brussels (Belgium): The Commission; 2012 Sept. Report No.: SWD ( 2012) 273 final
-
European Commission. Impact assessment on the revision of the regulatory framework for medical devices. Brussels (Belgium): The Commission; 2012 Sept. Report No.: SWD (2012) 273 final.
-
-
-
-
33
-
-
84896498789
-
-
European Commission, Enterprise and Industry Directorate-General. Recast of the Medical Devices Directives: summary of responses to the public consultation. Brussels (Belgium): The Commission; 2008 Dec. Report No.: ENTR/F/3/D( 2008) 39582
-
European Commission, Enterprise and Industry Directorate-General. Recast of the Medical Devices Directives: summary of responses to the public consultation. Brussels (Belgium): The Commission; 2008 Dec. Report No.: ENTR/F/3/D(2008) 39582.
-
-
-
|